Potentiation by (-)Pindolol of the activation of postsynaptic 5-HT(1A) receptors induced by venlafaxine.

Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montréal, Québec, Canada.
Neuropsychopharmacology (Impact Factor: 7.83). 10/2000; 23(3):294-306. DOI: 10.1016/S0893-133X(00)00112-3
Source: PubMed

ABSTRACT The increase of extracellular 5-HT in brain terminal regions produced by the acute administration of 5-HT reuptake inhibitors (SSRI's) is hampered by the activation of somatodendritic 5-HT(1A) autoreceptors in the raphe nuclei. The present in vivo electrophysiological studies were undertaken, in the rat, to assess the effects of the coadministration of venlafaxine, a dual 5-HT/NE reuptake inhibitor, and (-)pindolol on pre- and postsynaptic 5-HT(1A) receptor function. The acute administration of venlafaxine and of the SSRI paroxetine (5 mg/kg, i.v.) induced a suppression of the firing activity of dorsal hippocampus CA(3) pyramidal neurons. This effect of venlafaxine was markedly potentiated by a pretreatment with (-)pindolol (15 mg/kg, i.p.) but not by the selective beta-adrenoceptor antagonist metoprolol (15 mg/kg, i.p.). That this effect of venlafaxine was mediated by an activation of postsynaptic 5-HT(1A) receptors was suggested by its complete reversal by the 5-HT(1A) antagonist WAY 100635 (100 microg/kg, i.v.). A short-term treatment with VLX (20 mg/kg/day x 2 days) resulted in a ca. 90% suppression of the firing activity of 5-HT neurons in the dorsal raphe nucleus. This was prevented by the coadministration of (-)pindolol (15 mg/kg/day x 2 days). Taken together, these results indicate that (-)pindolol potentiated the activation of postsynaptic 5-HT(1A) receptors resulting from 5-HT reuptake inhibition probably by blocking the somatodendritic 5-HT(1A) autoreceptor, but not its postsynaptic congener. These results support and extend previous findings providing a biological substratum for the efficacy of pindolol as an accelerating strategy in major depression.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Glycosides of various classes of natural products are widely distributed in nature, where they are often present esterified with aliphatic and aromatic acids at specific OH's of their sugar moieties.Many of these compounds are pharmacologically important molecules or possess other interesting properties. For instance, ginsenosides (e.g., 3) are therapeutic dammarane-type oligoglycosides isolated from the water-soluble portion of the dried roots and leaves of Panax ginseng C.A. Meyer (Araliaceae), a plant widely used in traditional Chinese medicine.In recent years, we have exploited the regioselectivity of lipases and proteases in organic solvents for the synthesis of specific esters of ginsenosides as well as the selectivity of the β-1,4-galactosyltransferase from bovine colostrum to obtain new glycosyl derivatives of these compounds.The application of these two enzymatic methodologies has also been exemplified with other natural compounds with pharmacological properties: digitonin (5), colchicoside (6), and flavonoid glycosides.
    Annals of the New York Academy of Sciences 11/1998; 864(1):70 - 80. DOI:10.1111/j.1749-6632.1998.tb10289.x · 4.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are four main obstacles in achieving optimal drug doses in the development of antidepressant drugs. The first is the large placebo response. This is known to be proportional to the initial severity of the illness such that subjects with less severe depressive illnesses show the greatest placebo response. Up to 40% of depressed patients with mild illnesses will spontaneously remit over 4 weeks of placebo therapy. Treatment with an effective antidepressant produces rates of 60–70% in this population. Thus, improvement directly attributable to a pharmacological action of the drug occurs in only 20–30% of treated patients. The second difficulty is that depression is probably heterogeneous in its response to antidepressant drugs. There is reasonable evidence that depression with psychosis is poorly responsible at least to existing antidepressant drug therapies but specifically responsive to electroconvulsive therapy. Patients with bipolar affective disorder may switch into mania when treated with antidepressant drugs and some bipolar patients develop chronic depression which is very resistant to drug therapy. The third difficulty, which is not unique to antidepressant drugs, is that 4 weeks of therapy is probably insufficient to observe maximal response and improvement in depression may continue for 6–8 weeks. Improvement in other disorders such as obsessional compulsive disorder may continue well beyond 8 weeks. The fourth difficulty is that the pharmacological mechanism of action of antidepressants has some uncertainty and so it is difficult to develop in vivo surrogate markers. Modern imaging techniques offer a way forward. For example, new drugs can be investigated for their ability to displace radioligand binding to the receptor identified with antidepressant response. Positron emission tomography radioligands are being developed for monoamine reuptake sites and this could be used to optimise drug dosage with new monoamine uptake blocking antidepressants. There is a strong thrust of evidence which implicates post-synaptic 5HT1A receptor in mediating the antidepressant effects of drugs and these can already be visualised in using the radioligand WAY100635. The ability of antidepressant drugs to increase 5HT release could be detected by a displacement of WAY100635 by increased endogenous release of 5HT. Pharmaco magnetic resonance imaging is an emerging technology for dose optimisation of CNS drugs. The direct effect on neuronal metabolism in different regions of the brain can be monitored by following the local changes in blood flow. However, the technique is not yet quantitative. Another approach is to evoke regional neuronal activation using psychological tasks which engage different brain circuits or by the experimental induction of low mood itself.
    International Congress Series 08/2001; 1220(1220):223-245. DOI:10.1016/S0531-5131(01)00299-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study was designed to study potentiation of fluoxetine's antidepressant effect by curcumin or pindolol. Twenty eight groups of mice (n=8) were used in three sets of experiments. In the first set, 9 groups were subjected to the forced swimming test after being treated intraperitoneally with three vehicles, fluoxetine (5 and 20 mg/kg), curcumin (20 mg/kg), pindolol (32 mg/kg), curcumin+fluoxetine (5 mg/kg) and pindolol+fluoxetine (5 mg/kg). One hour after the test, serum and brain fluoxetine and norfluoxetine levels were measured in mice receiving fluoxetine (5 and 20 mg/kg), curcumin+fluoxetine (5 mg/kg) and pindolol+fluoxetine (5 mg/kg). In the second set, the test was done after pretreatment with p-chlorophenylalanine. In the third set, the locomotor activity was measured. The immobility duration was significantly decreased in fluoxetine (20 mg/kg), curcumin (20 mg/kg), curcumin+fluoxetine (5 mg/kg) and pindolol+fluoxetine (5 mg/kg) groups. These decreases were reversed with p-chlorophenylalanine. Fluoxetine and norfluoxetine levels were significantly higher in fluoxetine (20 mg/kg) group with no differences in fluoxetine (5 mg/kg), curcumin+fluoxetine (5 mg/kg) and pindolol+fluoxetine (5 mg/kg) groups. Moreover, drugs failed to alter the locomotor activity indicating absence of central stimulation. In conclusion, curcumin, more than pindolol enhanced the antidepressant effect of a subeffective dose of fluoxetine in mice without increasing its serum or brain levels excluding any pharmacokinetic interaction. Reversal of this potentiation with p-chlorophenylalanine suggests a pharmacodynamic interaction through involvement of presynaptic 5-HT1A receptors.
    Indian Journal of Pharmaceutical Sciences 05/2014; 76(3):203-10. · 0.30 Impact Factor